Top Performers in Small Cap Biotech: Five Rising Stars from 2025

The small cap biotech sector demonstrated remarkable resilience throughout 2025, with emerging companies driving innovation across multiple therapeutic areas. As the broader market navigated volatility, clinical-stage and late-stage biotech firms captured investor attention through breakthrough developments and strategic partnerships. This comprehensive review examines five of the year’s strongest performers in small cap biotech, analyzing their clinical pipelines, recent milestones, and the factors driving investor interest.

NASDAQ Biotech Index Surges to Three-Year Highs

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) reflects the sector’s overall momentum. After plunging to 3,637.05 in October 2023, the index recovered steadily through 2024, peaking near 4,954.813 on September 19. Despite pulling back to 4,530.69 in the summer of 2025, the index staged a powerful rebound in the second half of the year, ultimately closing at 5,766.59 on December 29—representing a 34% gain for the entire year. This recovery was driven substantially by advancements in immunotherapy, rare disease treatments, and innovative drug delivery platforms developed by emerging biotech companies.

Why Small Cap Biotech Stocks Matter in 2025

The rise of small cap biotech reflects a fundamental shift in pharmaceutical innovation. Unlike larger pharmaceutical companies constrained by legacy product portfolios, smaller biotech firms operate with specialized focus: single therapeutic platforms or targeted disease indications. This specialization enables faster clinical progression and earlier market entry for novel treatments. The data from 2025 demonstrates that investors increasingly recognize value in these focused, innovation-driven companies.

SELLAS Life Sciences Group: Teaching the Immune System to Fight Cancer

Stock Performance: 210.19% gain | Market Cap: $477.18 million | Share Price: $3.35 (as of December 29, 2025)

SELLAS Life Sciences Group exemplifies the potential within small cap biotech through its novel cancer immunotherapy approach. Rather than directly attacking cancer cells, the company’s platform teaches the immune system to recognize and eliminate tumor-specific proteins. The flagship therapeutic, galinpepimut-S (GPS), functions as a vaccine-like immunotherapy for acute myeloid leukemia (AML) patients in remission who face high relapse risk.

The company’s secondary asset, SLS009, operates as a CDK9 inhibitor targeting various blood cancers and currently advancing through Phase 2 trials. SELLAS’s remarkable 210% annual return was substantially influenced by December developments. On December 29, 2025, the company announced updated Phase 3 REGAL trial data for GPS as a maintenance therapy. The trial, designed as a blinded survival study triggered at 80 patient deaths, had reached 72 deaths by December 26—suggesting patients enrolled in the study were experiencing significantly longer survival than historical baselines. This outcome indicates the therapy may substantially impact AML patient outcomes.

IO Biotech: Combination Immunotherapy Advances Toward Registration

Stock Performance: 129.47% gain | Market Cap: $144.28 million | Share Price: $2.16

IO Biotech operates at the intersection of immuno-oncology and personalized medicine, leveraging its proprietary T-win technology platform to activate T cells against both tumor cells and immunosuppressive populations. The lead candidate, IO102-IO103 (Cylembio), received FDA breakthrough therapy designation when combined with Merck’s anti-PD-1 therapy Keytruda for advanced melanoma treatment.

The company reached a critical inflection point in August 2025 with Phase 3 trial readout. When administered alongside Keytruda, Cylembio demonstrated median progression-free survival of 19.4 months compared to 11 months for Keytruda monotherapy—a clinically meaningful improvement. However, the trial narrowly missed the predefined statistical significance threshold, a common occurrence in late-stage oncology development. Rather than viewing this as a setback, the biotech community and investors recognized the substantial clinical benefit signal.

Following a December FDA meeting, IO Biotech charted a path forward involving a new registrational trial designed to address the Phase 3 result. Simultaneously, the company expanded its pipeline, presenting preclinical data in November for IO112 (targeting arginase 1) and IO170 (targeting transforming growth factor). These pipeline expansions demonstrate management’s confidence in the platform and commitment to addressing multiple cancer indications.

Tiziana Life Sciences: Neuroinflammation Pioneer

Stock Performance: 124.64% gain | Market Cap: $184.22 million | Share Price: $1.55

Tiziana Life Sciences represents the diversity within small cap biotech through its focus on autoimmune, inflammatory, and neurodegenerative diseases. The cornerstone of the company’s approach is intranasal foralumab—a fully human anti-CD3 monoclonal antibody that offers a non-intravenous delivery alternative. This innovation addresses a significant unmet need in patients for whom repeated IV administration creates substantial burden.

Throughout 2025, Tiziana advanced foralumab across multiple clinical programs. In March, the company filed an investigational new drug application with the FDA for a Phase 2 amyotrophic lateral sclerosis (ALS) trial, supported by the ALS Association. The Phase 2 trial was slated to commence in January 2026. Simultaneously, Phase 2a dosing initiated in August for multiple system atrophy, another neurodegenerative indication.

The most compelling 2025 developments centered on multiple sclerosis and Alzheimer’s disease. Johns Hopkins University and University of Massachusetts commenced Phase 2 foralumab dosing for non-active secondary progressive MS in April. Following treatment initiation, the company announced May results indicating improved quality of life metrics for MS patients. Perhaps most intriguingly, emerging data from an Alzheimer’s patient treated with intranasal foralumab revealed significant microglia activation reduction on PET imaging after three months of therapy.

An unexpected discovery emerged from immunologic analysis: elevated phagocytosis markers in classical monocytes suggested foralumab might enhance immune cells’ capacity to clear amyloid plaques. This unexpected therapeutic mechanism—simultaneously addressing neuroinflammation while potentially removing amyloid accumulation—opened novel therapeutic avenues for Alzheimer’s treatment. Tiziana dosed the first patient in its Phase 2 Alzheimer’s randomized trial in December and submitted a comprehensive safety report documenting over 37 patient-years of exposure without serious drug-related adverse events.

Spero Therapeutics: Addressing the Antibiotic Resistance Crisis

Stock Performance: 119.05% gain | Market Cap: $129.58 million | Share Price: $2.30

Spero Therapeutics tackles a critical global health challenge: multidrug-resistant bacterial infections with limited therapeutic options. The company’s lead asset, tebipenem pivoxil hydrobromide (HBr), represents a late-stage development candidate created through collaboration with pharmaceutical giant GSK. This oral carbapenem targets complicated urinary tract infections (cUTIs) including pyelonephritis—conditions where treatment options are increasingly constrained by resistance patterns.

The FDA granted tebipenem HBr both qualified infectious disease product and fast-track designations, expediting the regulatory pathway. The pivotal moment arrived on May 28, 2025, when Spero announced that its Phase 3 trial met the primary endpoint for cUTI treatment, triggering early trial termination for efficacy. The stock surged 245%, reflecting investor recognition of the regulatory progress.

Subsequent developments accelerated the commercial timeline. On December 19, GSK filed a new drug application resubmission with the FDA for tebipenem HBr supported by Phase 3 efficacy data. This submission triggered a $25 million milestone payment to Spero, anticipated in Q1 2026. For a company with a market cap of $129.58 million, this milestone payment represents meaningful capital to fund operations and potentially advance secondary programs.

OKYO Pharma: Corneal Nerve Regeneration and Neuropathic Pain

Stock Performance: 60.5% gain | Market Cap: $74.85 million | Share Price: $1.91

OKYO Pharma pursues an underexplored therapeutic niche: neuropathic corneal pain and dry eye disease. The company’s lead candidate, urcosimod, functions as a non-steroidal anti-inflammatory and non-opioid analgesic—addressing a treatment gap for conditions currently managed with limited options.

After ending its Phase 2 trial early for interim data analysis, the company presented positive top-line results on July 17, 2025. The FDA granted fast-track designation in May following this promising data. The company subsequently announced a 120-patient multi-center multiple ascending dose trial in September, designed to establish optimal dosing for Phase 3 registration.

A remarkable scientific breakthrough materialized on December 11, 2025. New corneal imaging data revealed that urcosimod treatment produced median increases in corneal nerve fiber count and length—suggesting the therapy actively restores corneal nerve structure rather than simply alleviating symptoms. Placebo-treated patients demonstrated median decreases in both parameters. This mechanism of action—actual nerve regeneration—represents a paradigm shift in understanding urcosimod’s therapeutic potential and may support expanded development into other neuropathic conditions. Additionally, OKYO secured $1.9 million in non-dilutive funding in July to sustain clinical development momentum.

The Broader Context: Investing in Small Cap Biotech

The 2025 performance of these five small cap biotech companies reflects broader market recognition of innovation potential within emerging firms. Each company pursued highly specialized therapeutic strategies: cancer immunotherapy, novel drug delivery, rare infectious disease treatment, and neuropathic pain management. This portfolio diversity demonstrates that small cap biotech encompasses multiple therapeutic modalities and disease areas, reducing sector concentration risk.

The clinical data across these companies—Phase 3 efficacy signals, FDA breakthrough designations, and novel mechanism discoveries—underscores why investors increasingly view small cap biotech as vehicles for capturing pharmaceutical innovation. While smaller market capitalizations entail greater volatility and execution risk, the potential for transformative therapeutic breakthroughs and rapid regulatory advancement attracts capital seeking exposure to cutting-edge medicine development.